AlloArc Rheumatology Note (Standard)
About this template
Sample note
Chief Complaints:
Follow-up.
Hand swelling
HPI:
58-year-old female with a past medical history of seropositive rheumatoid arthritis and chronic hepatitis B, presents to clinic for follow-up. The patient also reports increased hand swelling.
1. RHEUMATOID ARTHRITIS FLARE:
- Increased pain and swelling in both hands over the past 6 weeks, with morning stiffness now lasting about 2 hours, previously under 30 minutes; difficulty opening jars and fastening buttons, with fatigue on most days.
- Taking methotrexate 20 mg orally once weekly on Sundays with folic acid 1 mg daily; missed 3 weekly doses in April 2026 while taking antibiotics for a dental infection.
- Adalimumab stopped in 09/2025 after about 8 months because of injection-site reactions.
- CRP 22 mg/L (05/2026), 6 mg/L (01/2026), 31 mg/L (06/2025).
2. CHRONIC HEPATITIS B:
- Taking tenofovir 300 mg daily without missed doses; followed by gastroenterology.
Review of Systems:
Constitutional: Reports fatigue. Denies fever.
Mouth/Throat: Denies oral ulcers.
Respiratory: Denies shortness of breath.
Musculoskeletal: Reports hand joint pain, joint swelling, and morning stiffness.
Skin: Denies rash.
Assessment:
ICD M05.79-Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement:
ICD B18.1-Chronic viral hepatitis B without delta-agent:
Treatment/Plan:
ICD M05.79-Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement:
- 28-joint exam today: 6 tender joints (bilateral second and third MCPs and both wrists) and 4 swollen joints (bilateral second and third MCPs); CDAI 24.
- Increased methotrexate from 20 mg orally to 25 mg subcutaneously once weekly on Sundays given persistent synovitis; continue folic acid 1 mg daily.
- Ordered CBC and comprehensive metabolic panel in 4 weeks.
- Deferred biologic therapy until reviewed with gastroenterology given chronic hepatitis B.
- Counseled on holding methotrexate during an active infection or antibiotic course.
- Follow-up in 6 weeks.
- Prior therapies: hydroxychloroquine 400 mg daily (2023 to 2024; inadequate response); adalimumab 40 mg subcutaneously every 2 weeks (01/2025 to 09/2025; injection-site reactions).
- Prior studies: Hand radiographs 11/2025: erosions at the second and third MCPs bilaterally.
ICD B18.1-Chronic viral hepatitis B without delta-agent:
- Gastroenterology (Dr. Alvarez) last seen 02/2026: continued tenofovir 300 mg daily; next visit 08/2026.
- Prior studies: Hepatitis B surface antigen positive with undetectable HBV DNA (01/2026).
This sample note was written by the template’s author and screened for patient information before publishing. Actual output may vary depending on patient encounter and clinical context.